Introduction
The large majority of human cancer diagnosed each year may be avoidable, but avoidable causes of many common cancers have not yet been clearly identified. A prerequisite of cancer prevention lies in identifying the determinants of cancer risk. Cancer control embraces a number of important elements with the aim of reducing the incidence of cancer and, failing primary prevention, reducing mortality either by finding disease at an earlier and more 'curable' stage or by improving the survival stage-for-stage through improvements in therapy. There are a number of disciplines involved within this embrace including epidemiology, clinical science, behavioural science and health education. It is a complex, and at times, uncoordinated package.
Screening for cancer involves the examination of, but more frequently the performance of a test on, asymptomatic individuals in order to classify them as likely or unlikely to have the disease in question. Those who appear likely to have the disease are investigated further to arrive at a final diagnosis and those who are found to have the disease are treated. The organized application of early diagnosis and treatment activities in large groups is often described as population screening. The goal of screening generally is to reduce mortality from the disease among the people screened by early treatment of the cases discovered. Screening calls attention to the likelihood of disease before symptoms appear.
Screening in connection with early diagnosis and treatment should be clearly distinguished from other uses of the term in epidemiology and clinical practice. In particular, 'screening' is commonly used to describe a series of tests done on a symptomatic patient for whom a diagnosis is not yet established. This type of screening is part of the practice of clinical medicine rather than public health or preventive medicine. Screening procedures may also be used to estimate the prevalence of various conditions without immediate disease-control objectives. Screening could be used both to refer to the identification of people at high risk of a disease but who do not yet have it and to the application of tests to this group for the early detection of disease.
It is also important to distinguish between diagnostic tests and screening tests. Morrison [1] illustrates this using the example of diabetes. The use of a glucose tolerance test is considered to be a diagnostic test while use of the (random) blood sugar method may be considered a screening test. Thus a liver biopsy would be considered a diagnostic test for liver cancer and a biopsy of the prostate a diagnostic test for prostate cancer. It is also essential to distinguish between what is meant by 'screening' and 'case-finding'. Screening is aimed at the general population and not merely those who have sought some medical attention.
The criteria which should be fulfilled before screening for a particular form of cancer were outlined by Wilson and Jungner [2] (Table 1 ). These criteria cover a variety of issues including the utility and acceptability of the screening test, knowledge of the natural history and treatment outcome of cancer and the cost, economical and due to treatment and false positive tests. These criteria have stood the test of time.
Current situation in screening for cancer
Cancer can be detected earlier than usual either when an individual recognises symptoms and then quickly consults and is diagnosed by a physician or through the application of a screening test, aimed at diagnosing pre-cancerous changes or cancer itself in generally asymptomatic individuals. Public education can be used to increase awareness of symptoms and their importance but the effects of such strategies have not been consistently evaluated. Despite not having detailed scientific evaluation, there are important reasons for improving public knowledge and awareness of abnormal signs and symptoms. However, issues in population screening are once more of critical concern to physicians and public health specialists at the present time.
Cervix cancer
In 1996, the National Institutes of Health (NIH) Consensus Statement [3] concluded that carcinoma of the cervix is causally related to infection with the human papillomavirus (HPV). Reducing the rate of HPV infection by changes in sexual behaviours in young people and/or through the †Disclaimer. Many of the ideas presented herein have been published previously and elsewhere by the author. Thus, it is important to note that the author does not claim this as original work but merely a compilation of ideas brought together for educational purposes (June 2002).
development of an effective HPV vaccine would reduce the incidence of this disease.
Pap smear screening remains the best available method of reducing the incidence and mortality of invasive cervical cancer. The test is named after George Nicolas Papanicolaou, who was born on May 13, 1883 in Kymi, Greece. He began his medical career taking care of patients at a leper colony north of his hometown of Kymi. Papanicolaou was very sympathetic to the lepers, who received little care from the surrounding community, and spent a lot of time tending to their medical and other personal needs.
In 1920, Dr Papanicolaou began his study of the vaginal cytology of the human. After becoming familiar with normal cytology changes, he found some cases of malignancy. About this discovery, he remarked, "The first observation of cancer cells in a smear of the uterine cervix was one of the most thrilling experiences of my scientific career." In 1928 he published a paper about the results of his work, entitled New Cancer Diagnosis.
In 1939, the re-evaluation of the vaginal smear for cancer detection began. At the New York Hospital all women patients were required to take a routine vaginal smear. Dr Herbert Traut, a gynaecological pathologist, collaborated with Dr Papanicolaou to validate the diagnostic potential of the vaginal smear. In 1943, they published their findings and conclusions in the famous monograph, Diagnosis of Uterine Cancer by the Vaginal Smear. The diagnostic procedure was named the Pap test.
Today screening for cervix cancer by examination of a cervical smear is widely recognised as leading to a reduction in the mortality from cervical cancer [4] . It has also been demonstrated to be cost-effective in older women particularly among those who have not been screened regularly [5] . The impact is greatest where organised screening programmes exist with personal letters of invitation: this leads to an improved attendance particularly among those women who are at high risk of cervical cancer [6] .
It has been shown, particularly from the Nordic countries, that a population-based and well-organised screening programme, with a valid target age range, the right frequency of screening and built-in quality assurance programmes at each stage of the screening process, is more successful than opportunistic screening and that it can be effective in reducing both the incidence and mortality from invasive cervical cancer. It would appear that the most successful programme in terms of reduction in risk of cervix cancer is in Finland, with an official recommendation that a screening programme be started at age 30 and that the smear be repeated every 5 years [6] .
If cytological screening programmes are seen to be effective in preventing invasive cervical cancer and cervical cancer mortality, numerous reports have underscored that that method may fail to detect a certain number of cervix cancers, mainly of the glandular type [7] . For instance, screening histories were examined in a case-control study where the cases were all women with invasive cervical cancer in 24 health districts of the health boards of Scotland, England and Wales in 1992. It was estimated that the number of cases of invasive cervical cancer would have been 57% greater if there had been no previous screening: in women under 70 years it would have been approximately 75% [8] . The study further estimated that full adherence to current screening guidelines could have prevented 1250 cases of invasive cervical cancer in the UK in the same year but that further steps would have to be sought to prevent some of the remaining 2300 cases in women under the age of 70. Most frequent reasons evoked to explain the lack of sensitivity of cytological screening refer to inadequate cell sampling with the spatula and to errors in the reading of smear slides. However, even in the best hands, a certain number of false negative cytological tests cannot be explained by sampling or reading problems. Hence, there is a strong feeling in the medical community that besides searching to improve screening coverage, there is also need for additional ways to improve screening methods for cervical cancer. The types of improvement suggested are an improvement of the spatula used for cell sampling (with current preference for instruments like the extended tip spatula) and the automation of cytological reading. It remains, however, to be assessed whether these improvements in the cytological methods will solve all types of false negative results.
Methods based on other approaches to cervical cancer screening are under investigation: some may eventually be employed as adjuncts to the pap smear test. One of them is Table 1 . Screening criteria of Wilson and Jungner (1968) [2] • Is the disease an important public health problem?
• Is there an effective treatment for localised disease?
• Are facilities for further diagnosis and treatment available?
• Is there an identifiable latent or early symptomatic stage of disease?
• Is the technique to be used for screening effective?
• Are the tests acceptable to the population?
• Is the natural history of the disease known?
• Is there a strategy for determining which patients should and should not be treated?
• Is the cost of screening acceptable?
• Is effective treatment available and does management of cases in the early stages have a favourable impact on prognosis? cervicography, which is popular in the USA and in some screening clinics in Europe. Although numerous groups have published results on screening with cervicography, wellconducted studies to evaluate cervicography (as compared with cytology) have remained rare [9] . The principal findings of these studies is that cytology and cervicography detect different pre-malignant lesions of the cervix. Hence, cervicography represents an interesting adjunct test to cytology, able to reduce the number of false negative results of the screening process. However, cervicography is not a simple technique as it requires a large experience of making readings, and that experience is essential to keep the level of unnecessary referrals to colposcopy-biopsy as low as possible.
Several other new technologies have shown some early promise, although they are in an earlier stage of being assessed as to their potential value in the early detection of cervix cancer. For example, the Polarprobe is an instrument which is based on a mathematical recognition algorithm for detecting anomalies in the cervix. An initial pilot study with a prototype of the PolarProbe instrument has shown false positive and false negative rates in the order of 10% for the detection of pre-malignant lesions of the cervix [10] , which provides strong encouragement for the development of studies to further examine the potential role of PolarProbe in the detection of high-grade cervical lesions. Speculoscopy was developed in the USA around 1992 in an attempt to increase the sensitivity of the pap smear by using chemical luminescence. It is currently being assessed in the screening setting in a variety of studies.
While this latter technique is being investigated as a tool for assisting in the collection of a cervical smear, the technology may also have a potentially important application in cervical cancer detection in developing countries where it could be very useful in improving the quality of a visual inspection of the cervix. Any way to advance the detection of cervical cancer, or pre-invasive cervical lesions, in the developing world would be particularly important: such regions typically have the highest rates of invasive cervical cancer [11] .
Given the implication of HPV infection in cervical cancer, detecting HPV could represent an appealing screening method. A study of 2009 women having routine screening in England and Wales revealed that 44% of cervical intraepithelial neoplasia (CIN) lesions of grade 2/3 detected had a negative cytology and were found only by HPV testing (for types 16, 18, 31 and 33): a further 22% were positive for HPV but demonstrated only borderline or mild cytological changes [12] . However, 25% of CIN 2/3 lesions were not detected by the four HPV tests. Hence, there is convergence between the results obtained when comparing HPV testing to cytology, and cervicography to cytology. However, although appealing, routine HPV testing for cervical cancer screening is still controversial as HPV infection is very common in women <30 years of age, and what really matters are those women over the age of 30 with a HPV infection that persists over a long period of time. As it is impossible currently to identify those women with a HPV infection who will develop cervix cancer, HPV testing is proposed to be used in various ways. For instance, as an adjunct to cytology for sorting out the cytological results classified as ASCUS, with referral to colposcopy-biopsy for ASCUS lesions positive for HPV infection. Another proposal consists in testing all women >30 years of age for HPV, and referring to cytology only those positive for HPV [13] . Hence HPV testing still needs to be thoroughly evaluated in order to find the exact role it could play in cervical cancer screening.
United Kingdom National Cervix Cancer Screening Programme
The United Kingdom National Cervix Cancer Screening Programme was established in 1988. The target population is women aged 25-64 in England, aged 20-64 in Wales and aged 20-59 in Scotland, who have been screened in the previous 5 years (5.5 years in Scotland). The Health of the Nation [14] target for cervix cancer is to reduce the incidence of invasive cervix cancer by at least 20% by the year 2000 (baseline 1986).
Participation in United Kingdom Cervix Cancer Screening Programme is high in England (84.0%), Wales (81.9%) and Scotland (86.6%). The most recent incidence data available from SOCRATES (the Scottish Cancer Registration System) is for 1998 and between the baseline year of 1986 and 1998 there was a decrease in incidence of 30.9%.
In conclusion, near maximal effectiveness in reducing incidence and mortality from cervix cancer can be achieved by an organised programme of cervical smear testing with high coverage, in which screening is initiated at the age of 25 and is repeated at 3-or 5-yearly intervals to the age of 60. Extension of this approach should be considered only if maximal coverage has been attained, the resources are available and the marginal cost-effectiveness of the recommended changes has been evaluated. HPV testing and other new technologies have still to be thoroughly evaluated although potentially some of these could usefully augment conventional cytology.
Breast cancer screening
There is considerable evidence that breast cancer screening with mammography is effective at reducing mortality from breast cancer, especially in circumstances where the quality of the mammography is high with good quality control. The best estimates from randomised trials are that the size of the reduction may be around 30% if take-up of screening in the population is good and quality control standards high. An overview of the Swedish trials reported relative risks of death of 0.71 in the group randomised to an offer of screening with a 95% confidence interval (CI) 0.57-0.89 for women aged 50-59 at entry. Results for women from 60 to 69 years of age were almost identical. When applied to a population it could be expected that a well-organised programme with a good compliance could lead to a reduction in breast cancer mortality of the order of 20% in women aged over 50 [15] . There is, as yet, no clear evidence that screening benefits older women and it is certain that they are less willing to attend for screening.
More importantly, results for younger women (<50 years of age) are ambiguous with no trials having large enough statistical power to analyse these women separately. The great controversy at the present moment revolves around what recommendations should be made for mammographic screening of women aged between 40 and 49. This is an important social problem: over 40% of the years of life lost due to breast cancer diagnosed before the age of 80 years are attributable to cases presenting symptomatically at ages 35-49 years, frequently an age of maximal social responsibility for women. In 1993, it was considered that there were no statistically significant results for this age group reported but point estimates included both reductions and increases in breast cancer mortality in women offered mammographic screening whilst under the age of 50 years [15] . Since then it has become clear that the natural history of breast cancer among women <50 and >50 years of age may be different. Re-analysis of the Swedish Two-County Trial has shed considerable light on two important issues. First, the mean sojourn time is estimated to be between 3 and 4 years for women aged ≥50 years but only about 20 months for women aged <50 years, after adjustment for tumour size and nodal status [16] . Furthermore, dedifferentiation often occurs at an early stage for women <50 years of age but later for women >50 years of age. This implies that the poorer performance of mammographic screening in younger women might be due to rapid progression and failure to arrest de-differentiation in this age group because the screening interval is too long [17] . It has also been demonstrated mathematically that the same benefit in terms of breast cancer mortality reduction could be expected among younger women if they were screened approximately every 18 months [17] .
A collaborative meeting was held in Falun, Sweden early in 1996, for which data were submitted from all randomised trials of breast screening that included women from 40 to 49 years of age. Updated results from the Swedish Overview indicated that relative mortality associated with invitation to screening was 0.77 (95% CI 0.59-1.01). Combining all population-based randomised trials produced a relative mortality of 0.76 (95% CI 0.62-0.93) and when all trials were combined, the relative mortality was 0.85 (95% CI 0.71-1.01). It was concluded that mammographic screening of women from 40 to 49 years of age could reduce subsequent mortality from breast cancer and that it was probably necessary to screen every 12-18 months in this age range, with two-view mammography and double reading of films, to obtain substantial benefits [18] .
This position was not accepted by the United States National Cancer Institute Consensus meeting held in January 1997, which ended in controversy and some acrimony [19] , but was upheld as a basis for recommendations to women by the American Cancer Society in March, 1997. Clearly, there are some remaining uncertainties surrounding this issue but women, and their families, deserve better ways to receive reliable information and clear recommendations about such an important issue than are available at present.
With regard to other methods of breast cancer screening, a recent large trial of taught breast self-examination demonstrated a reduction in mortality among women who had been trained in breast self-examination although the authors concluded that the study would continue and that stronger results may emerge as follow-up continues [20] . The effect of taught breast self-examination is also currently being evaluated in a randomised trial in Russia [21] .
United Kingdom National Mammographic Screening Programme
The evidence for mammographic screening was sufficiently strong that the European Code Against Cancer [22] included the following recommendation: "Check your breasts regularly. Participate in organised mammographic screening programmes if you are over 50". On the premise that breast cancer screening with mammography is effective at reducing mortality from breast cancer, especially in circumstances where the quality of the mammography is high with good quality control, a National Mammographic Screening programme was introduced into the United Kingdom in 1988 [23] . It has been estimated that, by 2004, the second round of screening in East Anglia should reduce breast cancer mortality by around 7% in women below 55 at diagnosis and by around 19% in those aged from 55 to 64 years [24] .
A National Breast Cancer Screening programme was launched in the UK in 1988, following publication of the Forrest Report [23] . The target population of the programme is women between 50 and 64 years of age who have been screened in the previous 3 years. Currently, participation is good: England (67.6%), Wales (69.9%), Scotland (71.1%) and Northern Ireland (70.5%).
The Health of the Nation Target [14] for breast cancer was to reduce the death rates for breast cancer in the population invited for screening by at least 25% by the year 2000 (Baseline 1990). The most recent mortality data available from the GRO (Scotland) is for 2000 and between the baseline year of 1990 and 1999 there was a decrease in mortality of 24.4% by Poisson regression (mortality rates have been agestandardised to the European Standard Population and cover the age group 55-69 years which is based on a recommendation of the evaluation group of the NHS Breast Screening Programme and demonstrated a 25.7% decline without using regression estimation).
Global Summit on Mammographic Screening
Clinical and pathological considerations clearly demonstrate that survival following the diagnosis and treatment of breast cancer at an early stage is very much better than when the disease is locally advanced or metastatic. Mammography can detect tumours at a clinically undetectable stage; such tumours have a very good prognosis and many should be cured by appropriate treatment. The results from the early randomised trials of mammographic screening were sufficiently promising to lead to the introduction of organised national programmes of screening in several countries in 1986-1988. Reports from seven trials involving over half a million women subsequently indicated a reduction in mortality from breast cancer of 20-30% in women invited to be screened. The reduction of mortality in those actually attending screening is clearly greater.
However, doubts regarding the validity of five of these trials have recently been raised by Gotzsche and Olsen, firstly in an article to the Lancet [25] 
Following the controversial publication of Gotzsche and Olsen, Swedish workers have conducted an overview of four of their trials. Their conclusions, published in the Lancet [27] indicate that the benefit of breast screening, in terms of a reduction in breast cancer mortality of 21%, persisting for a median time of 15.8 years. They also argued convincingly that the criticisms made against the Swedish trials by Gotzsche and Olsen are misleading and scientifically unfounded.
In addition to this overview, two Working Groups have been convened, the proceedings of which are as yet unpublished. A working group of the International Agency for Cancer Research (IARC), which consisted of 24 experts from 11 countries, met in Lyon on 5-12 March 2002. The quality of the seven trials was carefully assessed, as a result of which it was concluded that many of the criticisms raised by Gotzsche and Olsen were unsubstantiated. Further, those criticisms of substance did not invalidate the evidence that screening by mammography reduced mortality from breast cancer in women of 50-69 years of age. In women who participated in screening programmes, this was estimated to be a reduction of 35%. For women of 40-49 years of age, evidence for a reduction in mortality was limited. It was recognised that the effectiveness of national programmes of screening would vary according to differences in coverage and compliance, the quality of the mammograms, methods of assessment and treatment and many other factors. But such organised programmes were more likely to be effective in reducing the rate of death than was the sporadic screening of selected groups of women.
In addition, the United States Preventive Services Task Force (USPSTF), which has a mission 'to produce evidencebased reviews of preventative interventions provided in primary care clinical settings, using explicit, transparent, and publicly accountable methods' has also assessed the current evidence on mammographic screening. Key elements in this assessment are an evaluation of the quality of the available evidence and the performance of a meta-analysis wherever possible. They concluded that mammographic screening could be recommended as a Category B intervention on the grounds that the quality of evidence was fair and the net gain moderate. The reduction in breast cancer mortality among women invited to screening appeared to be 23%. Their statement reads: "The USPSTF recommends screening mammography, with or without clinical breast examination, every 1-2 years for women aged 40 and older. The USPSTF concludes that the evidence is insufficient to recommend for or against routine clinical breast examination alone. The USPSTF concludes that the evidence is insufficient to recommend for or against teaching or performing routine breast self-examination."
In response to the uncertainty over the efficacy of breast screening, a Global Summit on Mammographic Screening was organised in Milan on 3-5 June 2002. The Summit was planned in association with the World Health Organisation, the European Commission, the American Cancer Society, the Centers for Disease Control and Prevention, the American Italian Cancer Foundation, the European Society for Medical Oncology, the American Society for Clinical Oncology and the International Union Against Cancer.
The design and recent results from the seven randomised trials were presented and discussed in detail in the light of each criticism put forward by Gotzsche and Olsen. Some were discarded as being wrong, others had been addressed by new analyses and shown to be of minor significance. It was appreciated that conducting such large trials over many years is difficult, particularly as technology, treatment and indeed Public Health Policy can change during their course. But there was unanimity that the remaining minor considerations did not detract from the conclusion that screening mammography reduced the mortality from breast cancer in women receiving an invitation to be screened in well-organised clinical trials: the reduction in breast cancer mortality appeared to be between 21 and 23% according to recent estimates. Those participating fully could expect greater benefit.
Apart from a suggestion that the review by Gotzsche and Olsen in the Cochrane Library be revised, those attending the Milan Summit believed that the criticisms which they had raised had been fully addressed, that the 'book' on screening trials should now be closed, and that future activities should concentrate on the evaluation of organised programmes of mammographic screening, on exploring methods to ensure full participation, particularly amongst deprived women and on the development of new technologies for early diagnosis. During the meeting there were presentations of 14 such organised programmes of population screening; those of longer duration demonstrating tentative trends towards mortality reduction. Viable data from more recently established programmes tended to have similar values for many of the intermediate end points (e.g. stage of disease) as seen in the longer-established programmes, which was encouraging.
The World Health Organisation (WHO) Collaborating Centre for Cancer Prevention and Control has had a work programme approved to determine methods to evaluate organised screening programmes. Representatives of organised programmes would be invited to a meeting in November 2002, the work schedule to include developing the minimal data set required to evaluate such programmes, creating a database and identifying those programmes which were better or worse than expected and the reasons for such differences.
During the discussions at the Milan Global Summit, several participants stressed that mammographic screening was only one step in the total management of woman with breast cancer. As had been shown from long-term established programmes in the UK, Sweden, Finland and the Netherlands, recognition of the importance of the multidisciplinary team in the assessment of mammographic abnormalities had 'spun over' into the symptomatic sector leading to the development of integrated multidisciplinary breast care centres. Staffed by dedicated surgeons, radiologists and pathologists working alongside breast care nurses, counselling and other support personnel, these centres offered optimum care for women with breast cancer.
Mammographic screening: summary of the current situation
Forty years of clinical trials, the contribution of hundreds of scientists and health workers and the dedication of hundreds of thousands of women to participate in studies lasting for decades has resulted in adequate evidence to support the efficacy of mammographic screening for breast cancer, which now allows its transfer to the arena of Public Health Care. Doctors and women can now be assured that participation in organised screening programmes with high quality control standards is of benefit, provided appropriate investigation and treatment is available. Special effort should be made to encourage screening among the more deprived. It is important not to overemphasise the benefit of screening, and to appreciate that this is but one step in the total care of women with the disease. Women should, however, be informed clearly of the level of benefit and of potential risks and costs.
The Milan Global Summit, having examined recent results from all seven randomised trials of screening, concluded that evidence of benefit was convincing and that it was now time to move on. Attention should now focus on the further development of organised programmes of mammographic screening on a population basis, with insistence on quality assurance and meticulous evaluation.
Colorectal cancer
Colorectal cancer is the fourth commonest form of cancer worldwide, with an estimated 782 900 new cases diagnosed in 1990 [28] . The disease is not uniformly fatal although there are large differences in survival according to stage of disease. In advanced colorectal cancer in which curative resection is possible, 5-year survival in Dukes' B is 45% which drops to 30% in Dukes' C [29] . Five-year survival in resected Dukes' A is around 80% and survival following simple resection of an adenomatous pedunculated polyp containing carcinoma in situ (or severe dysplasia) or intramucosal carcinoma is generally close to 100%. Although it has been argued that death from colorectal cancer may be avoidable [30] , it is estimated that there are still 394 000 deaths from colorectal cancer worldwide annually [31] .
The identification of a well-determined pre-malignant lesion, the adenomatous polyp, together with the good survival associated with early disease, make colorectal cancer an ideal target for screening. In the past quarter century, great progress has been made in our ability to screen patients for colorectal cancer or its precursor state, using advances in imaging and diagnostic technology. Greegor [32, 33] first employed the faecal occult blood guaiac test cards and the flexible sigmoidoscope was introduced in the mid-1970s to replace the rigid sigmoidoscope which had been first introduced in 1870, and colonoscopy has been available since 1970 [34] .
Four randomised trials have examined annual or biennial screening with faecal occult blood testing (FOBT) while there are only early data available regarding sigmoidoscopy and colonoscopy, and little yet from randomised trials. There is evidence from these randomised trials to support the use of FOBT [35] [36] [37] with a reduction in colorectal cancer mortality of around 16% (95% CI 7% to 23%) from a meta-analysis [23% (95% CI 11% to 43%) reduction among those screened] [38] and a reduction in incidence reported but only after 18 years of follow-up [39] . Concerns remain about the high rate of false-positive results, the feasibility and the small clinical benefit of such screening. These concerns were outlined recently [40] and it was calculated that 1173 individuals needed to be tested for 10 years to avoid one death from colorectal cancer.
Various organisations have considered recommendations for colorectal cancer screening. A recent report to the Europe Against Cancer Advisory Committee on Cancer Prevention [41] recommended that "FOBT should be seriously considered as a preventive measure". In an accompanying editorial, Coebergh [42] was not completely persuaded by this advice pointing out that the modest effects seen were potentially due to the more intensive follow-up of controls in some of the trials [43] .
Subsequently, some important findings have been reported. Lieberman et al. [44] examined the sensitivity of FOBT and sigmoidoscopy for detecting neoplasia with 2885 asymptomatic subjects who provided stool specimens on cards which underwent rehydration. They then underwent colonoscopy with sigmoidoscopy defined as examination of the rectum and sigmoid colon during colonoscopy. Of the subjects with advanced neoplasia 23.9% had a positive test for occult blood. As compared with subjects who had a negative test for faecal occult blood, the relative risk of advanced neoplasia in subjects who had a positive test was 3.5 (95% CI 2.8-4.4). Sigmoidoscopy identified 70% of all subjects with advanced neoplasia. Combined FOBT and sigmoidoscopy identified 75.8% of subjects with advanced neoplasia. The authors concluded that one-time screening with both faecal occult blood (with rehydration) and sigmoidoscopy fails to detect advanced colonic cancer in 24% of subjects with the condition [44] . This is an important finding which requires further confirmation and detailed investigation.
Detsky [45] considered that there were five important reasons why colonoscopy was not routinely recommended as a screening tool: the standard of evidence, adherence, risk, economics and availability. The issue of standard of evidence is one which requires much attention in epidemiology at the present time. Faecal occult blood testing has been evaluated in randomised trials whereas colonoscopy has not. Detsky [45] concluded that the higher sensitivity of colonoscopy plus the evidence that early detection improves survival is sufficient to conclude that colonoscopy is more effective than FOBT. In addition, there is support from observational studies.
Screening with sigmoidoscopy has been demonstrated in case-control and non-randomised studies to reduce the incidence and mortality from colorectal cancer by over 50% [46] [47] [48] : FOBT does not appear to reduce the incidence of colorectal cancer although there are important questions to be resolved [49] . Should FOB testing now be recommended as a population screening method? Should consideration be given to other screening modalities for colorectal cancer? Since a large proportion of individuals tested for FOB have positive tests and are referred for colonoscopy, could it prove effective to bypass FOB testing and go directly to a screening colonoscopy? Or flexible sigmoidoscopy? This latter strategy is currently being assessed in a large, randomised trial and it is a clear reflection of the tremendous potential for colorectal cancer early detection by screening, which is clearly outlined in detail elsewhere [50] . This should continue to be a priority research activity at present.
To bring all the arguments about colorectal cancer screening with FOBT to the readership, the Annals of Oncology invited twelve international groups to outline their position: nine accepted immediately and three declined to do so (on the grounds of pressing priorities). The groups were chosen on their expertise in the area of colorectal cancer and groups who have been involved in trials of colorectal cancer screening were excluded from consideration.
One common thread in all these articles relates to the economics of FOBT. La Vecchia [51] outlined the basic epidemiological data, both from observational studies and randomised trials, and indicated where there are key gaps in knowledge.
McArdle [52] noted key issues such as compliance among deprived members of communities and the utility of two pilot studies ongoing in the UK at present to address such issues.
Lowenfels [53] invited reflection on "why don't we screen for this potentially preventable cancer?" emphasising that this is a major practical issue. He lays out the arguments in an epidemiological manner as to why screening is necessary, why FOBT may not be the best test and weighs the potential benefits of other tests. Leading gastroenterologists, Bleiberg [54] , Crespi and Lisi [55] and Strul and Arber [56] , adopted a more clinical approach and presented good overviews and interpretations of the available data. Strul and Arber [56] also gave an interesting glimpse of new stool-based tests which may soon be available for population assessment and use.
Autier [57] and Barry [58] took a broader Public Health perspective. Arguing that FOBT produces modest changes in mortality rates, Autier concludes that FOBT is less efficient than screening tests for other cancers such as pap smear for cervix cancer and mammography for breast cancer [57] . Barry points out that "most Americans have not been screened for colorectal cancer by any means" and the situation is identical throughout the rest of the world. Unfortunately, as Barry [58] emphasises, there is a gap between what the (Public Health) doctor prescribes and what the patient is willing to do. While this situation persists, and scientific squabbles continue about the best way to screen populations for colorectal cancer, the chance is being missed to prevent a significant number of the 400 000 colorectal cancer deaths which occur each year throughout the world.
Screening for other forms of cancer
While there are screening tests proposed for a number of different forms of cancer, there are no randomised trial data to support screening at other sites as a public health measure. There has been apparent success in Japan with screening for stomach cancer but this has not been carefully evaluated [4] . There are screening tests available and being evaluated for oral cancer, nasopharynx cancer and neuroblastoma [4] . The issues in screening have been well outlined in two recent monographs [59, 60] .
Screening for prostate cancer
At the present time there is great pressure to screen for prostate cancer, although widespread implementation of screening programmes for prostate cancer cannot be recommended based on the available evidence: little has changed since the most recent review of the topic by an expert committee of the International Union Against Cancer (UICC) which came to the same conclusion [4] . Unfortunately there are national practices which are at complete variance: in the USA 'screening' with prostate specific antigen (PSA) is widespread [61] , while in the UK there is a strong bias against 'screening' with PSA [62] essentially on evidence-based grounds.
The main reason for this situation is that no results are available from randomised trials assessing screening for prostate cancer. These are the only methods of evaluation which avoid bias and, in consequence, it is not known whether screening by whichever of the available modalities or their combinations is effective in reducing the mortality rate of prostate cancer.
Obviously, this is a necessary pre-requisite for embarking on population screening or even screening high-risk groups (even if such a group can be defined for prostate cancer).
Screening for prostate cancer at a population level would be expensive and consume a large proportion of available resources for health: it is essential to have some indication of effectiveness and efficacy before embarking on such programmes. Although there is no evidence available at present from randomised trials to indicate that any lives will be saved by such screening it is logical to suppose that early detection and effective treatment could be effective. The current situation in the USA in favour of PSA screening has been compared with the enthusiasm and the similarity of the arguments put forward in favour of lung cancer screening several years ago [63] ; this bright promise did not subsequently materialise.
From 1993 onwards, routine PSA testing was made freely available to the male population of Tyrol, Austria, aged from 45 to 74 years [64] . By comparing prostate cancer mortality in Tyrol, where PSA testing was introduced, with the rest of Austria where it was not, the impact of screening could be monitored in a natural experiment. Initially only total PSA was measured but free PSA measurement was added in 1995. The IMx assay was used. Digital rectal examination (DRE) was not part of the screening examination.
There has been a reduction in mortality rates in the rest of Austria from 1993 onwards with a greater reduction in Tyrol. Trends in prostate cancer mortality rates since 1993 differ significantly between Tyrol (P = 0.006) and the rest of Austria [64] . The mortality reduction has remained significantly reduced in 2000. Quite similar trends in prostate cancer mortality are found in geographically adjacent states to Tyrol (Voralborg, Carinthia, Salzburg) where there was some participation in the screening programme, while there is a similar and lower reduction in mortality in the remaining six States, where there was no participation.
These findings are consistent with the hypothesis that the policy of making PSA testing freely available, and the wide acceptance by men in the population, is associated with a sustainable reduction in prostate cancer mortality in an area where high-quality diagnostics, urology and radiotherapy are available freely to all patients [64] . This latter situation makes Tyrol somewhat unique and is a sine qua non for considering implementation of such programmes.
Screening for lung cancer
It has long been established that the best way to control lung cancer is to reduce cigarette smoking in the population, foremost through prevention, and secondarily through smoking cessation. However, even after they have stopped smoking, long-term smokers remain at high risk for lung cancer. Although prevention and cessation strategies are obvious investments for intervention, presently there is no agreed upon control policy for subjects already at high risk due either to prolonged exposure to tobacco smoke or occupational exposures. Lung cancer when clinically diagnosed has a poor outcome with 10-16% survival at 5 years. If the tumour is small enough to be removed surgically, the outcome is much better, >70% for stage 1 tumours. This led to speculation in the past as to whether long-term smokers or others at high risk might benefit from earlier detection.
In the 1970s, lung cancer screening focused on the chest X-ray, and several studies were carried out. These trials had discouraging results, suggesting that screening by chest X-ray did not lead to a significant reduction in lung cancer mortality. Increased numbers of tumours in the screened arms of the Czech Trial and Mayo Lung Project, both of which compared chest X-ray to usual care, suggested a degree of overdiagnosis of histologically confirmed lung cancers due to the screening [65, 66] . The Mayo project in particular had an excess of early stage tumours in the screened arm, but no deficit of late stage [66] . Although no clear evidence of benefit from early detection emerged from these studies, they had a number of methodological shortcomings so significant that an international lung cancer screening conference in Varese, Italy in December 1998 concluded that they were an "imperfect basis for public policy" [65] . The studies suggested shortcomings in chest X-ray as a screening tool, including doubts about sensitivity. This and other aspects of chest X-ray screening should be clarified when the lung cancer results of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) are published [65] .
With the development of low-dose spiral computerised tomography (CT) scanning, there is new hope for a sensitive screening tool for lung cancer [67] [68] [69] . In a Japanese study, 5-year survival of lung cancer cases diagnosed by CT screening was around 85% [69] . In the Early Lung Cancer Action Project (ELCAP), the stage of the non-small cell cancers diagnosed suggest that a similar outcome will be observed in these cases after 5-year follow-up [67, 68] . Due to potentially manageable costs, acceptable levels of radiation exposure and improved detection sensitivity, there are grounds for hope that this new technology might allow for detection at a sufficiently early stage to allow successful treatment of lung malignancies that would be certainly fatal otherwise. The ELCAP study demonstrated that spiral CT was able to identify very small lung cancers in high-risk volunteers, with a resectability rate of 96% and a proportion of stage I >80% [67] . However, in order to achieve those excellent results, high-resolution CT (HRCT) had to be applied to a high proportion of subjects with a complex algorithm of 3D reconstruction for minimal growth assessment, with a diagnostic period extending up to 2 years, and major expertise in fine-needle biopsy of small lesions. A recent meta-analysis has highlighted the diagnostic value of PET in undetermined pulmonary nodules [70] .
The great improvements in diagnostic imaging offer real possibilities to develop better screening technologies. This is particularly true in lung cancer where something needs to be done, especially for those who have quit smoking. Such advances in technology raise other issues; notably, how to evaluate a technology which will be outdated by the time the study is completed. The need to seek alternative, reliable methods of evaluation should be a major research focus at present.
Summary and conclusions
Screening for cancer is currently entering a very promising period as new technologies become available for assessment. However, this great opportunity also presents significant problems, starting with how do you select the likeliest method for evaluation? How do you do trials where the technology will be out-moded by the time the result is known? Indeed, how can all promising technologies be evaluated?
There is a need for a renewal of methodological thinking on this topic at present. Randomised trials, which currently rely on death as the primary outcome, are very long and very complicated to undertake and run. There is an urgent need for biological markers, which are true surrogate end points, to help reduce sample size and make trials more feasible and so that more trials can be done.
For those screening modalities of demonstrated effectiveness, the key issue at present is how to maximise the outcome in population screening when the technology is transferred from the research setting to the public health setting. It is essential to remember that screening per se has never prevented a cancer nor prevented a cancer death. It is impossible to separate the issues of screening from those of adequate treatment: the best results in a screening programme will come when treatment is excellent.
Screening is the first, and sometimes key, stage in a global management programme for the cancer in question. As we now strive to maximise the effectiveness of population-based programmes this aspect should be foremost in our thought process.
